Citations

Mayo Clinic

Showing 10 of 108551 citations.

Novel Bloodless Potassium Determination Using a Signal‐Processed Single‐Lead ECG
Sapir, Yehu , Dugan, Jennifer , Ackerman, Michael J. , Asirvatham, Samuel J. , Striemer, Bryan L., Bukartyk, Jan , Bennet, Kevin E. , Ladewig, Dorothy J., Gilles, Emily J., Sadot, Dan , Geva, Amir B. , Friedman, Paul A. , Dillon, John J, Dugan, Jennifer L, Bruce, Charles J. , Attia, Zachi I. , DeSimone, Christopher V. , Dillon, John J., Somers, Virend K. , Scott, Christopher G. , Asirvatham, Samuel J

Journal of the American Heart Association | January 25, 2016 | Volume: 5 | Issue: 1 | Pages: No page available

10.1161/jaha.115.002746 | PMID 26811164 Get It

Background Hyper‐ and hypokalemia are clinically silent, common in patients with renal or cardiac disease, and are life threatening. A noninvasive, unobtrusive, blood‐free method for tracking potassium would be an important clinical advance. Methods and Results Two groups of hemodialysis patients (development group, n=26; validation group, n=19) underwent high‐resolution digital ECG recordings and had 2 to 3 blood tests during dialysis. Using advanced signal processing, we developed a personalized regression model for each patient to noninvasively calculate potassium values during the second and third dialysis sessions using only the processed single‐channel ECG . In addition, by analyzing the entire development group's first‐visit data, we created a global model for all patients that was validated against subsequent sessions in the development group and in a separate validation group. This global model sought to predict potassium, based on the T wave characteristics, with no blood tests required. For the personalized model, we successfully calculated potassium values with an absolute error of 0.36±0.34 mmol/L (or 10% of the measured blood potassium). For the global model, potassium prediction was also accurate, with an absolute error of 0.44±0.47 mmol/L for the training group (or 11% of the measured blood potassium) and 0.5±0.42 for the validation set (or 12% of the measured blood potassium). Conclusions The signal‐processed ECG derived from a single lead can be used to calculate potassium values with clinically meaningful resolution using a strategy that requires no blood tests. This enables a cost‐effective, noninvasive, unobtrusive strategy for potassium assessment that can be used during remote monitoring.
Opioid-induced constipation: advances and clinical guidance
Nelson, Alfred D. , Camilleri, Michael

Therapeutic Advances in Chronic Disease | January 25, 2016 | Volume: 7 | Issue: 2 | Pages: 121-134

10.1177/2040622315627801 | PMID 26977281 Get It

Currently opioids are the most frequently used medications for chronic noncancer pain. Opioid-induced constipation is the most common adverse effect associated with prolonged use of opioids, having a major impact on quality of life. There is an increasing need to treat opioid-induced constipation. With the recent approval of medications for the treatment of opioid-induced constipation, there are several therapeutic approaches. This review addresses the clinical presentation and diagnosis of opioid-induced constipation, barriers to its diagnosis, effects of opioids in the gastrointestinal tract, differential tolerance to opiates in different gastrointestinal organs, medications approved and in development for the treatment of opioid-induced constipation, and a proposed clinical management algorithm for treating opioid-induced constipation in patients with noncancer pain.
Are Zebras Simply Striped Horses?
Lane, Colleen E. , Olson, Eric J. , Gersh, Bernard J. , Michelena, Héctor I.

Circulation | January 25, 2016 | Volume: 133 | Issue: 4 | Pages: 434-441

10.1161/circulationaha.115.018730 | PMID 26811273 Get It

MicroRNA Expression Signatures During Malignant Progression From Barrett's Esophagus
Bansal, Ajay , Gupta, Vijayalaxmi , Wang, Kenneth T.

Journal of Cellular Biochemistry | January 25, 2016 | Volume: 117 | Issue: 6 | Pages: 1288-1295

10.1002/jcb.25497 | PMID 26808728 Get It

ABSTRACTThe rapid increase and poor survival of esophageal adenocarcinoma (EAC) have led to significant efforts to promote early detection. Given that the premalignant lesion of Barrett's esophagus (BE) is the major known risk factor for EAC, multiple investigators have studied biomarker signatures that can predict malignant progression of BE to EAC. MicroRNAs, a novel class of gene regulators, are small non‐coding RNAs and have been associated with carcinogenesis. MicroRNAs are ideal biomarkers because of their remarkable stability in fixed tissues, a common method for collection of clinical specimens, and in blood either within exosomes or as microRNA‐protein complexes. Multiple studies show potential of microRNAs as tissue and blood biomarkers for diagnosis and prognosis of EAC but the results need confirmation in prospective studies. Although head‐to‐head comparisons are lacking, microRNA panels require less genes than messenger RNA panels for diagnosis of EAC in BE. MicroRNA diagnostic panels will need to be compared for accuracy against global measures of genome instability that were recently shown to be good predictors of progression but require sophisticated analytic techniques. Early studies on blood microRNA panels are promising but have found microRNA markers to be inconsistent among studies. MicroRNA expression in blood is different between various microRNA sub‐compartments such as exosomes and microRNA‐protein complexes and could affect blood microRNA measurements. Further standardization is needed to yield consistent results. We have summarized the current understanding of the tissue and blood microRNA signatures that may predict the development and progression of EAC. J. Cell. Biochem. 117: 1288–1295, 2016. © 2016 Wiley Periodicals, Inc.
Immune checkpoint blockade in lymphoid malignancies
Thanarajasingam, Gita , Thanarajasingam, Uma , Ansell, Stephen M.

The FEBS Journal | January 25, 2016 | Volume: 283 | Issue: 12 | Pages: 2233-2244

10.1111/febs.13668 | PMID 26807978 Get It

Malignant cells may subvert and escape endogenous host immune surveillance by up‐regulation of immune inhibitory signals known as immune checkpoints. These checkpoints are important therapeutic targets, and antibodies that block checkpoint signaling have shown remarkable efficacy in some solid tumors as well as in some refractory hematologic malignancies. In hematologic cancers, the mechanism of these checkpoints is complex, as the tumor and immune system are one and the same. In this review, we evaluate the biology of checkpoint inhibition, review the current data on its efficacy in lymphoid tumors, and explore uncertainties in the field, including those involving the precise mechanisms of action, the appropriate timing of therapy, and the differences in response rate between lymphoid tumor types.
Anesthetic considerations for patients with Bardet–Biedl syndrome: a case series and review of the literature
Smith, Bradford B. , Barbara, David W. , Hyder, Joseph A. , Smith, Mark M. , Smith, Mark M

Pediatric Anesthesia | January 25, 2016 | Volume: 26 | Issue: 4 | Pages: 429-437

10.1111/pan.12848 | PMID 26804322 Get It

SummaryBackgroundBardet–Biedl syndrome (BBS) is a rare genetic condition with manifestations that can impact anesthetic and perioperative care. There is a void of literature describing the perioperative anesthetic management in this complex patient population.ObjectivesThe purpose of this retrospective series was to describe the perioperative care of patients diagnosed with BBS at a large academic tertiary referral center with experience in caring for these patients.MethodsAll patients receiving anesthesia during the time between July 10, 1997 and Jan 1, 2015 were identified. Anesthetic and perioperative records were reviewed in detail for demographic, echocardiographic, preoperative, intraoperative, and postoperative data.ResultsWe identified 12 patients with BBS undergoing 40 anesthetics at our institution. The study identified a high risk for difficult airway with need for advanced airway techniques (67% of patient's ≥18 years of age required either awake fiberoptic or video laryngoscopy techniques), cardiac abnormalities, renal impairment, morbid obesity, and intellectual disability as the main syndrome manifestations of interest to the anesthesiologist. No patient had perioperative complications directly related to BBS; however, each underwent thorough perioperative evaluation with emphasis on the systemic comorbidities associated with the syndrome. This report illustrates that patients with BBS can safely undergo anesthesia, but a detailed and often multidisciplinary preoperative evaluation is prudent.
Perceived Appropriateness of Shared Decision‐making in the Emergency Department: A Survey Study
Kanzaria, Hemal K., Frosch, Dominick L. , Winkel, Gary, Ngai, Ka Ming , Richardson, Lynne D. , Probst, Marc A. , Hess, Erik P.

Academic Emergency Medicine | January 25, 2016 | Volume: 23 | Issue: 4 | Pages: 375-381

10.1111/acem.12904 | PMID 26806170 Get It

AbstractObjectivesThe objective was to describe perceptions of practicing emergency physicians (EPs) regarding the appropriateness and medicolegal implications of using shared decision‐making (SDM) in the emergency department (ED).MethodsWe conducted a cross‐sectional survey of EPs at a large, national professional meeting to assess perceived appropriateness of SDM for different categories of ED management (e.g., diagnostic testing, treatment, disposition) and in common clinical scenarios (e.g., low‐risk chest pain, syncope, minor head injury). A 21‐item survey instrument was iteratively developed through review by content experts, cognitive testing, and pilot testing. Descriptive and multivariate analyses were conducted.ResultsWe approached 737 EPs; 709 (96%) completed the survey. Two‐thirds (67.8%) of respondents were male; 51% practiced in an academic setting and 44% in the community. Of the seven management decision categories presented, SDM was reported to be most frequently appropriate for deciding on invasive procedures (71.5%), computed tomography (CT) scanning (56.7%), and post‐ED disposition (56.3%). Among the specific clinical scenarios, use of thrombolytics for acute ischemic stroke was felt to be most frequently appropriate for SDM (83.4%), followed by lumbar puncture to rule out subarachnoid hemorrhage (73.8%) and CT head for pediatric minor head injury (69.9%). Most EPs (66.8%) felt that using and documenting SDM would decrease their medicolegal risk while a minority (14.2%) felt that it would increase their risk.ConclusionsAcceptance of SDM among EPs appears to be strong across management categories (diagnostic testing, treatment, and disposition) and in a variety of clinical scenarios. SDM is perceived by most EPs to be medicolegally protective.
Long-term Benefits of Risk Factor Reduction in Takotsubo Cardiomyopathy.—A Comment on Khalighi et al. Entitled “Takotsubo Cardiomyopathy: A Long Term Follow-up Shows Benefit with Risk Factor Reduction”, J. Cardiovasc. Dev. Dis., 2015, 2, 273–281.
Ponamgi, Shiva , Deshmukh, Abhishek , Ponamgi, Shiva P

Journal of Cardiovascular Development and Disease | January 25, 2016 | Volume: 3 | Issue: 1 | Pages: 3

10.3390/jcdd3010003 | PMID 29367555 Get It

Takotsubo cardiomyopathy (TC) or stress-induced cardiomyopathy is also popularly referred to as “broken heart syndrome” or “apical ballooning syndrome”. [...]
Colorectal cancer outcomes and treatment patterns in patients too young for average‐risk screening
Abdelsattar, Zaid M. , Wong, Sandra L. , Regenbogen, Scott E. , Jomaa, Diana , Hardiman, Karin M. , Hendren, Samantha , Wong, Sandra

Cancer | January 25, 2016 | Volume: 122 | Issue: 6 | Pages: 929-934

10.1002/cncr.29716 | PMID 26808454 Get It

BACKGROUNDAlthough colorectal cancer (CRC) screening guidelines recommend initiating screening at age 50 years, the percentage of cancer cases in younger patients is increasing. To the authors' knowledge, the national treatment patterns and outcomes of these patients are largely unknown.METHODSThe current study was a population‐based, retrospective cohort study of the nationally representative Surveillance, Epidemiology, and End Results registry for patients diagnosed with CRC from 1998 through 2011. Patients were categorized as being younger or older than the recommended screening age. Differences with regard to stage of disease at diagnosis, patterns of therapy, and disease‐specific survival were compared between age groups using multinomial regression, multiple regression, Cox proportional hazards regression, and Weibull survival analysis.RESULTSOf 258,024 patients with CRC, 37,847 (15%) were aged <50 years. Young patients were more likely to present with regional (relative risk ratio, 1.3; P<.001) or distant (relative risk ratio, 1.5; P<.001) disease. Patients with CRC with distant metastasis in the younger age group were more likely to receive surgical therapy for their primary tumor (adjusted probability: 72% vs 63%; P<.001), and radiotherapy also was more likely in younger patients with CRC (adjusted probability: 53% vs 48%; P<.001). Patients younger than the recommended screening age had better overall disease‐specific survival (hazards ratio, 0.77; P<.001), despite a larger percentage of these individuals presenting with advanced disease.CONCLUSIONSPatients with CRC diagnosed at age <50 years are more likely to present with advanced‐stage disease. However, they receive more aggressive therapy and achieve longer disease‐specific survival, despite the greater percentage of patients with advanced‐stage disease. These findings suggest the need for improved risk assessment and screening decisions for younger adults. Cancer 2016;122:929–34. © 2016 American Cancer Society.